30: Ozempic (Part 1)

The Ozempic episode is HERE (Part 1). By this point, most of us have heard of the celebrities taking Ozempic/ Wegovy. If not, you must not watch the news or be on social media...lucky you! These drugs are being called "a miracle" and the "end of the ob*sity epidemic". Is this true?  Abbey is joined by her intern, Nicole, to discuss all things weight loss drugs. Together they cover: what Ozempic is, how it works for diabetes and for weight loss, the difference between Ozempic and Wegovy, common side effects, and more. There's a lot of discourse in this episode, so buckle up! TW: "ob*se and ov*rweight terms are used in the episode to describe the research and BMI qualifiers.  Be sure to rate the podcast and subscribe! Join the Fork Diet Culture Community! Work with Abbey 1-on-1 More about Abbey Follow on IG and TT: @fork.diet.culture Collins L, Costello RA. Glucagon-Like Peptide-1 Receptor Agonists. [Updated 2023 Jan 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551568/ Shetty R, Basheer FT, Poojari PG, Thunga G, Chandran VP, Acharya LD. Adverse drug reactions of GLP-1 agonists: A systematic review of case reports. Diabetes Metab Syndr. 2022;16(3):102427. doi:10.1016/j.dsx.2022.102427 Kapoor I, Sarvepalli SM, D'Alessio D, Grewal DS, Hadziahmetovic M. GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials. Surv Ophthalmol. 2023;68(6):1071-1083. doi:10.1016/j.survophthal.2023.07.002 Suran M. As Ozempic's Popularity Soars, Here's What to Know About Semaglutide and Weight Loss. JAMA. 2023;329(19):1627-1629. doi:10.1001/jama.2023.2438 Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. doi:10.1111/dom.14725 Novo Nordisck. Ozempic. https://www.novocare.com/diabetes/products/ozempic.html Web site. Updated 2024 Gómez Lumbreras A, Tan MS, Villa-Zapata L, Ilham S, Earl JC, Malone DC. Cost-effectiveness analysis of five anti-obesity medications from a US payer's perspective. Nutr Metab Cardiovasc Dis. 2023;33(6):1268-1276. doi:10.1016/j.numecd.2023.03.012 Gordon A, Hobbs M. Maintenance Phase; Ozempic. 2023;Podcast